In Vivo Diagnosis of Synucleinopathies
A Comparative Study of Skin Biopsy and RT-QuIC

Vincenzo Donadio, MD, PhD,* Zerui Wang, MD, PhD,* Alex Incensi, BSc, Giovanni Rizzo, MD, Enrico Fileccia, MD, Veria Vacchiano, MD, Sabina Capellari, MD, PhD, Martina Magnani, BSc, Cesa Scaglione, MD, Michelangelo Stanzani Maserati, MD, Patrizia Avoni, MD, PhD, Rocco Liguori, MD,† and Wenquan Zou, MD, PhD†

Neurology® 2021;96:e2513-e2524. doi:10.1212/WNL.0000000000011935

Abstract

Objective
To determine whether (1) immunofluorescence is a reproducible technique in detecting misfolded α-synuclein in skin nerves and subsequently whether (2) immunofluorescence and real-time quaking-induced conversion (RT-QuIC) (both in skin and CSF) show a comparable in vivo diagnostic accuracy in distinguishing synucleinopathies from non-synucleinopathies in a large cohort of patients.

Methods
We prospectively recruited 90 patients fulfilling clinical and instrumental diagnostic criteria for all synucleinopathies variants and non-synucleinopathies (mainly including Alzheimer disease, tauopathies, and vascular parkinsonism or dementia). Twenty-four patients with mainly peripheral neuropathies were used as controls. Patients underwent skin biopsy for immunofluorescence and RT-QuIC; CSF was examined in patients who underwent lumbar puncture for diagnostic purposes. Immunofluorescence and RT-QuIC analysis were made blinded to the clinical diagnosis.

Results
Immunofluorescence showed reproducible results between 2 pairs of neighboring skin samples. Both immunofluorescence and RT-QuIC showed high sensitivity and specificity in discriminating synucleinopathies from non-synucleinopathies and controls but immunofluorescence presented higher diagnostic accuracy. Immunofluorescence presented a good level of agreement with RT-QuIC in both skin and CSF in synucleinopathies.

Conclusions
Both immunofluorescence and RT-QuIC showed high diagnostic accuracy, although immunofluorescence displayed the better value as well as optimal reproducibility; they presented a good level of agreement in synucleinopathies, supporting the use of less invasive tests such as skin immunofluorescence or RT-QuIC instead of CSF RT-QuIC as a diagnostic tool for synucleinopathies.

Classification of Evidence
This study provides Class III evidence that immunofluorescence or RT-QuIC accurately distinguish synucleinopathies from non-synucleinopathies.

*These authors contributed equally to this work as co-first authors.
†These authors contributed equally to this work as co-senior authors.

From the IRCCS Istituto delle Scienze Neurologiche di Bologna (V.D., A.I., G.R., E.F., V.V., S.C., M.M., C.S., M.S.M., P.A., R.L.), Italy; and Departments of Pathology and Neurology (Z.W., W.Z.), Case Western Reserve University School of Medicine, Cleveland, OH.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge will be funded by Ricerca Finalizzata Ministero della Salute Grant RF-2016-02362047.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
The diagnosis of synucleinopathies is mainly based on clinical criteria, leading to frequent misdiagnosis, as underlined by autopsy studies. Recent advances have been made by the development of tests able to detect in vivo pathologic $\alpha$-synuclein such as immunofluorescence analysis of skin nerves and real-time quaking-induced conversion (RT-QuIC) of CSF. An important advantage of RT-QuIC is the possibility to perform the simultaneous analysis of different samples from the same patient such as the easily available skin together with CSF obtainable by an invasive procedure although a direct comparative study has not been reported.

Immunofluorescence and RT-QuIC explore different aspects of pathologic $\alpha$-synuclein. Immunofluorescence may detect the morphology of pathologic aggregates in skin nerves whereas RT-QuIC can determine their seeding activity, a prion-like biological trait of misfolded proteins. Accordingly, the diagnostic accuracy of each test in disclosing the pathologic form of $\alpha$-synuclein may differ but a direct comparison is not yet available.

This study aimed to establish the reproducibility of immunofluorescence and subsequently to compare the diagnostic accuracy of immunofluorescence and RT-QuIC as biomarkers for synucleinopathies. Specifically, this study aims at comparing (1) the sensitivity and specificity of immunofluorescence and RT-QuIC to disclose pathologic $\alpha$-synuclein in different variants of synucleinopathies and (2) the diagnostic accuracy of RT-QuIC in disclosing the seeding activity of pathologic $\alpha$-synuclein in skin samples vs CSF.

**Methods**

We prospectively screened at the IRCCS Institute of Neurologic Sciences of Bologna (Italy), from 2018 to 2020, 100 consecutive patients with possible neurodegenerative disorders; only 90 reaching a high level of diagnostic accuracy fulfilling current clinical and instrumental diagnostic criteria for a specific $\alpha$-synucleinopathies or non-synucleinopathies were recruited for this study. The reproducibility of immunofluorescence findings was ascertained in 21 patients: 9 synucleinopathies (4 fulfilling diagnostic criteria for Parkinson disease [PD]), 4 for probable multiple system atrophy (MSA), and 1 for dementia with Lewy bodies (DLB) and 12 non-synucleinopathies (1 fulfilling diagnostic criteria for Alzheimer disease [AD], 8 for progressive supranuclear palsy [PSP], and 3 for corticobasal syndrome [CBD]). Immunofluorescence and RT-QuIC were then compared in an additional 69 patients. They included 31 patients with synucleinopathies: 17 with PD, 5 with DLB, 8 with probable MSA, and 3 with pure autonomic failure (PAF); and 38 patients with non-synucleinopathies, comprising 15 with AD with typical CSF findings, 6 with vascular parkinsonism, 1 with iatrogenic parkinsonism secondary to high dosage of neuroleptic drugs in treatment of psychotic disorders, 2 with vascular dementia, 7 with tauopathies or TDP proteinopathy (1 patient with frontotemporal dementia, 3 with PSP, 2 with CBD, and 1 with anti-IgLON5 antibody), and 6 fulfilling diagnostic criteria for amyotrophic lateral sclerosis (table 1). Recruited patients had no familial history for neurologic disorders.

Neurogenic orthostatic hypotension was established by a decrease of at least 20/10 mm Hg without significant change of heart rate on the head-up tilt test (3 minutes at 65°) in PD with orthostatic hypotension. Cognitive deterioration was ascertained by corrected Mini-Mental State Examination (±24) and by Brief Mental Deterioration Battery, a neuropsychological test standardized in the Italian population expressing global cognitive impairment when the final score is negative (<0).

The clinical diagnosis of recruited patients was supported by appropriate diagnostic instrumental tests (table 1). Ioflupane $^{[123]}$I SPECT of nigrostriatal dopaminergic activity showed abnormal findings in all synucleinopathies except in patients with PAF. The low rate of nigrostriatal SPECT scan in non-synucleinopathies was due to the lack of motor involvement in almost half of these patients showing an isolated dementia. Brain MRI showed typical abnormalities supporting the clinical diagnosis in DLB and AD (cortical atrophy), MSA (putaminal atrophy or hyperintense putaminal rim, hot cross bun sign, and brainstem atrophy), and tauopathies or TDP proteinopathy (cortical or brainstem atrophy). In addition, cardiac uptake of $^{[123]}$I-MIBG SPECT was done in 11 patients because sufficient diagnostic accuracy had already been achieved by means of other diagnostic tests or because patients were unable to perform the test. Cardiac MIBG SPECT showed a sympathetic denervation in all synucleinopathies (7 patients), except patients with MSA (4), displaying normal findings.

The presence of REM sleep behavior disorder (RBD) has been verified in all recruited patients by the clinical interview of patients and their bed partners. RBD was determined in 17
patients with synucleinopathies by the bed partner describing a history of frequent clear dream enactment (table 1). Polysomnographic study was performed in 5 patients reporting RBD (3 PD and 2 MSA) and confirmed REM sleep without atonia. Recruited patients were treated with levodopa with or without dopamine agonists for patients with parkinsonism and a variable combination of cholinesterase inhibitors, memantine, and selective serotonin reuptake inhibitor in patients with dementia.

For the comparative study, 24 patients with neurologic disorders without evidence of neurodegenerative diseases were also recruited. They included 7 patients with small fiber neuropathy due to diabetes or autoimmune diseases, 5 with idiopathic peripheral neuropathy, 1 with chronic inflammatory demyelinating polyneuropathy, 1 with Wernicke encephalopathy, 2 with cerebral vasculitis, 1 with stiff-person syndrome, 2 with subjective cognitive disorder, and 5 with severe depression showing normal cerebral MRI, cognitive tests, and CSF markers of neurodegeneration (table 1). All recruited patients underwent skin biopsy; lumbar puncture to collect CSF was performed only in patients when required for diagnostic purposes. CSF was thus available in 9 patients with synucleinopathies, 24 patients with non-synucleinopathies, and 16 controls. Immunofluorescence and RT-QuIC analysis were made blinded to the clinical diagnosis.

Primary research questions to be addressed in this study were the immunofluorescence reproducibility and the diagnostic accuracy of immunofluorescence and RT-QuIC to differentiate synucleinopathies from non-synucleinopathies and control patients. This study provides Class III evidence that immunofluorescence is reproducible and that immunofluorescence or RT-QuIC accurately distinguish synucleinopathies from non-synucleinopathies.

Table 1 Clinical and Demographic Data of Recruited Patients

| N | Age, y, mean ± SE | Sex, M:F | Disease duration, y, mean ± SE | RBD, % of patients | Nigrostriatal DaTscan, % abnormala | Brain MRI, % abnormala |
|---|---|---|---|---|---|---|
| **Immunofluorescence reproducibility** | | | | | | |
| Synucleinopathies | 9 | 69 ± 3 | 4:5 | 5 ± 1 | 55b | 100 | 44 |
| Non-synucleinopathies | 12 | 67 ± 3 | 7:5 | 4 ± 1 | 0 | 42 | 58 |
| **Immunofluorescence vs RT-QuIC** | | | | | | |
| Synucleinopathies | 31 | 67 ± 1 | 20:11 | 4 ± 1 | 65b | (28) 89 | (24) 71 |
| Non-synucleinopathies | 38 | 69 ± 1 | 17:21 | 3 ± 1 | 0 | (14) 64 | 89 |
| Controls | 24 | 65 ± 2 | 13:10 | 3 ± 1 | 0 | 0 | (13) 15 |

Abbreviations: RBD = REM sleep behavior disorder; RT-QuIC = real-time quaking-induced conversion.

a The number in parentheses represents the number of patients in whom the test was performed.

b p < 0.01 (synucleinopathies vs non-synucleinopathies or controls).

Standard Protocol Approvals, Registrations, and Patient Consents

This study received approval from an ethical standards committee on human experimentation (institutional) for any experiments using human subjects and the procedures followed the Helsinki Declaration related to clinical research of human beings. Written informed consent was obtained from all patients (or guardians) participating in the study (consent for research).

Skin Biopsy

Three-millimeter punch biopsies were taken from proximal and distal hairy skin sites. Patients recruited for this study underwent both routine diagnostic skin biopsy protocol and the study protocol used for this research (figure 1). The routine diagnostic protocol included a pair of skin samples, spaced about 3 cm on a horizontal line, taken from proximal (C7 paravertebral: 5 cm from the midline) and distal sites (thigh: 15 cm above the patella; and leg: 10 cm above the lateral malleolus). Two skin samples were taken in every single site to increase the rate of phosphorylated α-synuclein (p-syn) positivity as previously described.8,21 The study protocol provided 2 additional pairs of skin samples taken from a single skin site 2–3 cm apart for a total of 8 samples/patient (figure 1). The skin site from the study protocol was chosen for the study considering the probability of finding p-syn in skin nerves, which is influenced by the specific clinical phenotype.8 Accordingly, the proximal skin site was mainly chosen in patients with parkinsonism and dementia (C7, which corresponds to protocol III of figure 1), while in patients with autonomic or neuropathic disorders, the distal sites (L = distal leg and T = thigh, which correspond to protocols I and II, respectively, of figure 1) were mainly selected. However, when the patient was particularly compliant, 2 different skin sites were analyzed for the study protocol (10 samples/
Skin samples were taken from C7, thigh, and distal leg. We took in each skin site a second biopsy approximately 3 centimeters away from the first sample to increase the rate of phosphorylated α-synuclein (p-syn) positivity. The study protocol includes 2 pairs of skin samples taken from a single skin site (i.e., C7, thigh, or leg) 2–3 centimeters apart (red rectangle). In addition, in the remaining 2 skin sites, a pair of skin samples were taken for routine purpose (black rectangle). The skin site was chosen for the study considering the probability of finding p-syn in skin nerves, which is influenced by the specific clinical phenotype. Accordingly, the distal skin sites were mainly chosen in patients with autonomic or neuropathic disorders (protocols I and II), while in patients with parkinsonism and dementia, the proximal site was mainly used (protocol III). In 1 patient with Parkinson disease (PD) and 4 patients with progressive supranuclear palsy for the immunofluorescence reproducibility study and 2 patients with PD and 1 patient with Alzheimer disease for the comparative study 2 different skin sites were analyzed for the study protocol (10 samples/patient).

**Preparation of Skin and CSF Samples**

The skin punch biopsy samples (∼30 mg, ∼3×3 mm) included epidermis and dermis layers. The 2 frozen skin samples were prepared for RT-QuIC analysis as described previously with minor modifications. Each single skin sample was analyzed individually. The skin tissues washed for 3 times in 1× Tris-buffered saline (TBS) were separated into small pieces in dishes. The skin homogenates at 10% (w/vol) were prepared in skin lysis buffer containing 2 mM CaCl₂ and 0.25% (w/vol) collagenase A (Roche) in TBS and incubated at 37°C for 4 hours with shaking, followed by homogenization in a Mini-Beadbeater (BioSpec; Laboratory Supply Network, Inc., Atkinson, NH) for 1 minute. After sonication, the samples were centrifuged at 500g for 3 minutes to collect the supernatant fraction (S1). A total of ∼60–100 µL aliquot of CSF for each patient was kept at −80°C in a freezer for RT-QuIC assay.

**RT-QuIC Analysis**

The RT-QuIC analysis of skin or CSF samples was made as described previously with minor modifications. In brief, RT-QuIC reaction mix was composed of 40 mM phosphate buffer (pH 8.0), 170 mM NaCl, 0.1 mg/mL recombinant human wild-type α-synuclein purchased commercially (rPeptide, Watkinsville, GA), 10 µM Thioflavin T (ThT), and 0.00125% sodium dodecyl sulfate. Aliquots of the 98 or 85 µL reaction mix each were loaded into each well of a microtiter plate and incubated at 37°C in a shaking water bath. After RT-QuIC reaction, the microtiter plates were analyzed with Endpoint measurements using a microplate reader (Synergy H1, Biotek Inc., Winooski, VT).

**P-syn Staining**

P-syn staining was rated as positive when a single skin nerve fiber showed a positive staining at high magnification (×40) in the 2 close skin samples. Because of clear-cut differences among different groups with no p-syn positivity found in non-synucleinopathies and control patients, quantitative analysis of p-syn distribution was not performed for this study. However, for the co-localization of p-syn with PGP, we performed analysis by acquiring digital images using a laser-scanning confocal microscope (Nikon confocal microscopy, Eclipse Ti A1, Japan) as previously described.

**RT-QuIC Analysis of Seeding Activity of Pathologic α-Synuclein**

**IF Analysis to Search for P-Syn Deposits in Skin Nerves**

According to previously published procedures, skin samples were immediately fixed in cold Zamboni fixative and kept at 4°C overnight.

Ten-micrometer sections were obtained using a cryostat (CM 1950; Leica, Deerfield, IL). Three sections 500 µm apart from each skin sample were analyzed. They were double-immunostained overnight with a panel of primary antibodies including rabbit monoclonal phosphorylated α-synuclein at Ser 129 (p-syn; 1:500, Abcam, Cambridge, UK; cat. no. ab-51253) and mouse pan-neuronal marker protein gene product 9.5 (1:750; Abcam; cat. no. ab72911). Sections were then washed and secondary antibodies were added for an incubation of 1 hour. As for secondary antibodies, an anti-mouse Alexa Fluor 488 (1:400; Jackson ImmunoResearch, West Grove, PA; cat. num. 715-545-150) and rabbit cyanine dye fluorophores 3.18 (1:200, Jackson ImmunoResearch; cat. num. 711-165-152) were used. The microscopic analysis and criteria followed to define a p-syn positivity were described previously and mainly based on the correspondence between rabbit p-syn and mouse PGP staining. Two authors with expertise in immunofluorescent analysis (V.D. and A.I.) analyzed immunofluorescence images blinded to the clinical diagnosis. The intralaboratory analysis revealed an excellent reproducibility, with 100% concordance of classification in all patients (K = 1), in agreement with recently reported data. P-syn staining was rated as positive when a single skin nerve fiber showed a positive staining at high magnification (×40) in the 2 close skin samples. Because of clear-cut differences among different groups with no p-syn positivity found in non-synucleinopathies and control patients, quantitative analysis of p-syn distribution was not performed for this study. However, for the co-localization of p-syn with PGP, we performed analysis by acquiring digital images using a laser-scanning confocal microscope (Nikon confocal microscopy, Eclipse Ti A1, Japan) as previously described.
black 96-well plate with a clear bottom (Nunc) preloaded with ~5 glass beads (diameter 1 mm) and seeded with 2 μL of skin homogenate S1 or 15 μL of CSF. The skin homogenates or CSF samples were spun at 2000 g for 2 minutes at 4°C prior to making serial dilutions. The plate sealed with a plate sealer film (Nalgene Nunc International) was incubated at 42°C in a BMG FLUOstar Omega plate reader with cycles of 1 minute shaking (400 rpm double orbital) and 1 minute rest for the indicated incubation time. The measurements of ThT fluorescence (450 ± 10 nm excitation and 480 ± 10 nm emission; bottom read) were conducted every 45 minutes. Four replicate reactions were seeded with the same dilution for each individual sample. The average fluorescence value of each sample was calculated using fluorescence values from all 4 replicate wells regardless of whether these values crossed the threshold described below. The maximal fluorescence response (260,000 rfu) of the plate readers was plotted vs different time points of measurements. Seeding activity was classified as RT-QuIC positive based on criteria similar to those previously described for RT-QuIC analysis of brain specimens. Skin RT-QuIC was considered positive in case of reaction of at least 1 of 2 samples analyzed for each skin site. The fluorescence threshold for a positive reaction was based on the mean ThT value of all negative control samples at 60

### Table 2 Reproducibility of Phosphorylated α-Synuclein Staining in Close Skin Sample Pairs

| Synucleinopathies | C7 (protocol III) | Thigh (protocol II) | Leg (protocol I) |
|-------------------|-------------------|---------------------|-----------------|
| Biopsy 1 | Biopsy 2 | Biopsy 1 | Biopsy 2 | Biopsy 1 | Biopsy 2 |
| PD | + | + | – | – | + | + |
| | + | + | + | + | + | + |
| | + | + | + | + | + | + |
| | + | + | + | + | + | + |
| | + | + | + | + | + | + |
| MSA | + | + | + | + | + | + |
| | + | + | + | + | + | + |
| DLB | + | + | + | + | + | + |

### Non-synucleinopathies

| | C7 (protocol III) | Thigh (protocol II) | Leg (protocol I) |
|-------------------|-------------------|---------------------|-----------------|
| Biopsy 1 | Biopsy 2 | Biopsy 1 | Biopsy 2 | Biopsy 1 | Biopsy 2 |
| Alzheimer | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| PSP | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| CBD | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |
| | – | – | – | – | – |

Abbreviations: Biopsy 1 = pair of skin samples; Biopsy 2 = pair of skin samples next to the first pair; CBD = corticobasal syndrome; DLB = dementia with Lewy bodies; MSA = multiple system atrophy; PD = Parkinson disease; PSP = progressive supranuclear palsy.
hours, plus 3 SDs. At least 2 of 4 replicate wells must cross this threshold and lag phase in less than 50 hours in order for a sample to be considered positive. The RT-QuIC fluorescence signal reported for the analysis from each skin site was the largest value of the 2 samples analyzed.

### Statistical Analysis

This analysis was performed using SPSS 25.0. Kolmogorov-Smirnov test was used to verify the normal distribution of continuous variables. Student t test or 1-way analysis of variance followed by a post hoc Bonferroni test were used for comparison of normally distributed data. Mann-Whitney U test or Kruskal-Wallis test were utilized to compare variables without a normal distribution. Categorical variables were compared using χ² test and the results were presented as absolute and relative frequency (%). To adjust the results for age, sex, and disease duration, we further used logistic or multivariate linear regression depending on the data. Agreement was tested using Cohen k statistics. For all analyses, significance was assumed for p < 0.05, Bonferroni-corrected for multiple comparisons. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the different diagnostic techniques were calculated using the clinical diagnosis as the gold standard.

### Data Availability

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

### Results

Recruited patients and controls were matched for age and disease duration. Males were more prevalent in each group except for patients with non-synucleinopathies used for comparison between immunofluorescence vs RT-QuIC, in which females were more represented (table 1). As expected, RBD incidence was highly prevalent in synucleinopathies, and none of the non-synucleinopathies or control patients presented with this sleep disorder. Also as expected, nigrostriatal DaTscan abnormalities were more prevalent in patients with synucleinopathies than in those with non-synucleinopathies and controls, but cerebral MRI abnormalities were similar among recruited patients (table 1), although the specific type of abnormality differed in each group, as expected.

### Immunofluorescence Staining of Pathologic P-Syn in Skin Nerves

P-syn staining in skin nerves was reproducible between 2 pairs of neighboring skin samples in all sites (table 2). In all 29 skin sites analyzed (19 C7, 8 distal leg, and 2 thigh), p-syn showed the same results, supporting the comparison between a pair of skin samples analyzed with immunofluorescence with a neighboring pair analyzed with a different technique.

Considering samples selected for the comparison study, p-syn positivity was disclosed in all synucleinopathies except 3 patients (2 with MSA and 1 with PAF), but importantly, it was not found in any non-synucleinopathies or control patients. The patient with PAF negative for p-syn in the selected skin sample was instead positive in both additional routinely analyzed skin sites, that is, the C7 and leg, whereas patients with MSA showing no p-syn in selected samples were negative even in routinely analyzed C7 and thigh sites. Routine immunofluorescence analysis (including additional 2 or 4 skin samples and 6 or 12 skin sections) did not reveal any p-syn positivity in non-synucleinopathies and control patients in agreement with the results of skin samples selected for the study. The p-syn positivity differed among patients with synucleinopathies, being mainly detected in autonomic fibers of PD, DLB, and PAF, but detected in somatic fibers of the upper dermis in MSA, confirming previous data. The analysis of sensitivity and specificity showed that p-syn presented a high diagnostic accuracy in discriminating synucleinopathies from non-synucleinopathies and controls with 90% sensitivity and 100% specificity (table 3). Logistic regression model showed no influence of age, sex, or disease duration on the results.

### RT-QuIC Evaluation of Pathologic α-Synuclein Seeding Activity

#### RT-QuIC Assay of Skin Samples

The pathologic α-synuclein seeding activity of the skin punch biopsy samples from the 3 groups of patients was detected by RT-QuIC assay. The cutoff value for defining the positive seeding activity was 45,414 (attribute unit [au]) based on the mean α-synuclein seeding activity of control plus 3 SDs. The skin RT-QuIC assay yielded 86% sensitivity and 80% specificity (table 3) in disclosing synucleinopathies, lower than immunofluorescence due to 9 out of 38 patients with non-synucleinopathies showing positive α-synuclein ThT fluorescence reaction. In addition, 3 out of 24 control patients showed a positive α-synuclein ThT fluorescence reaction (table 4). Positive patients with non-synucleinopathies and controls did not show any clinical sign of parkinsonism, dysautonomia, or cerebellar dysfunction at the time of

---

**Table 3 Diagnostic Accuracy of Immunofluorescence and Real-Time Quaking-Induced Conversion (RT-QuIC)**

| Immunofluorescence skin | Skin RT-QuIC | CSF RT-QuIC |
|-------------------------|--------------|-------------|
| Sensitivity             | 90           | 86          | 78          |
| Specificity             | 100          | 80          | 100         |
| PPV                     | 100          | 67          | 100         |
| NPV                     | 95           | 92          | 95          |
| Accuracy                | 97           | 82          | 96          |

Abbreviations: NPV = negative predictive value; PPV = positive predictive value. Values are percentages.
| Variable                      | Cases, n | Diagnosis                        | Skin Protocol | Immunofluorescence | RT-QuIC | CSF, RT-QuIC |
|-------------------------------|----------|----------------------------------|---------------|--------------------|---------|--------------|
| **Synucleinopathies**         | 1        | PD (1 point)                     | III           | +                  | +       | +            |
|                               | 2        | PD (6 points)                    | III           | +                  | +       | ND           |
|                               | 3        | PD (1 point)                     | II            | +                  | +       | +            |
|                               | 4        | PD (3 points)                    | II            | +                  | +       | ND           |
|                               | 5        | PD (5 points)                    | III           | +                  | +       | ND           |
|                               | 6        | PD (1 point)                     | I             | −                  | +       | ND           |
|                               | 7        | MSA-C (1 point)                  | III           | +                  | +       | +            |
|                               | 8        | MSA-P (3 points)                 | I             | +                  | +       | ND           |
|                               | 9        | MSA-P (1 point)                  | I             | −                  | −       | ND           |
|                               | 10       | MSA-P (1 point)                  | I             | +                  | −       | ND           |
|                               | 11       | MSA-P (1 point)                  | I             | −                  | +       | ND           |
|                               | 12       | MSA-C (1 point)                  | I             | +                  | −       | ND           |
|                               | 13       | Lewy body dementia (1 point)     | III           | +                  | −       | ND           |
|                               | 14       | Lewy body dementia (2 points)    | II            | +                  | +       | +            |
|                               | 15       | Lewy body dementia (1 point)     | I             | +                  | +       | +            |
|                               | 16       | Lewy body dementia (1 point)     | I             | +                  | +       | ND           |
|                               | 17       | PAF (1 point)                    | II            | +                  | +       | +            |
|                               | 18       | PAF (1 point)                    | II            | −                  | −       | −            |
|                               | 19       | PAF (1 point)                    | I             | +                  | +       | ND           |
| **Non-synucleinopathies**     | 1        | AD (5 points)                    | III           | −                  | −       | −            |
|                               | 2        | AD (2 points)                    | III           | −                  | +       | −            |
|                               | 3        | AD (1 point)                     | III           | −                  | −       | ND           |
|                               | 4        | AD (1 point)                     | III           | −                  | +       | ND           |
|                               | 5        | AD (2 points)                    | II            | −                  | −       | −            |
|                               | 6        | AD (1 point)                     | II            | −                  | −       | ND           |
|                               | 7        | AD (2 points)                    | I             | −                  | −       | −            |
|                               | 8        | AD (1 point)                     | I             | −                  | −       | ND           |
|                               | 9        | PSP (1 point)                    | III           | −                  | +       | ND           |
|                               | 10       | PSP (2 points)                   | II            | −                  | −       | −            |
|                               | 11       | CBS (1 point)                    | II            | −                  | −       | ND           |
|                               | 12       | CBS (1 point)                    | II            | −                  | +       | ND           |
|                               | 13       | Vascular parkinsonism (3 points) | III           | −                  | −       | ND           |
|                               | 14       | Vascular parkinsonism (2 points) | II            | −                  | −       | ND           |
|                               | 15       | Vascular parkinsonism (2 points) | I             | −                  | −       | −            |
|                               | 16       | Iatrogenic parkinsonism (1 point)| I             | −                  | −       | ND           |

Continued
recruitment or careful clinical reassessment carried out after 14 ± 3 months (mean ± SE). The mean skin α-synuclein ThT fluorescence reaction from patients with synucleinopathies (n = 31) was significantly higher than that from patients with non-synucleinopathies (n = 38) (125.575 ± 10.525 [SE] vs 41.295 ± 5.674, au, \( p < 0.001 \), figure 2) and that from controls (n = 24) (125.575 ± 10.525 vs 29.073 ± 4.064, au, \( p < 0.001 \)) (figure 3A), respectively. RT-QuIC reaction was higher than in control patients even considering only the 3 positive controls (125.575 ± 10.525 vs 73.744 ± 13.047; \( p = 0.10 \)). In contrast, there was no significant difference in skin α-synuclein ThT fluorescence intensity between non-synucleinopathies and controls (41.295 ± 5.674 vs 29.073 ± 4.064, au, \( p = 0.359 \)) (figure 3A). Age, sex, and disease duration did not influence the results by using a logistic regression model.

| Variable | Cases, n | Diagnosis | Skin Protocol | Immunofluorescence | RT-QuIC | CSF, RT-QuIC |
|----------|----------|-----------|---------------|--------------------|---------|--------------|
| 17       | Autoimmune parkinsonism (1 point) | II | – | – | – |
| 18       | Vascular dementia (1 point) | III | – | – | – |
| 19       | Vascular dementia (1 point) | II | – | + | – |
| 20       | ALS (1 point) | III | – | + | – |
| 21       | ALS (1 point) | II | – | + | – |
| 22       | ALS (3 points) | I | – | – | – |
| 23       | ALS (1 point) | I | – | + | ND |
| Controls |          |          |               |                    |         |              |
| 1        | Small fiber neuropathy (3 points) | III | – | – | – |
| 2        | Small fiber neuropathy (2 points) | III | – | – | ND |
| 3        | Small fiber neuropathy (1 point) | I | – | – | – |
| 4        | Small fiber neuropathy (1 point) | I | – | – | ND |
| 5        | Peripheral neuropathy (1 point) | III | – | + | ND |
| 6        | Peripheral neuropathy (1 point) | II | – | – | – |
| 7        | Peripheral neuropathy (1 point) | II | – | + | – |
| 8        | Peripheral neuropathy (1 point) | I | – | – | – |
| 9        | Peripheral neuropathy (1 point) | I | – | – | ND |
| 10       | CIDP (1 point) | I | – | – | – |
| 11       | Wernicke encephalopathy (1 point) | I | – | – | – |
| 12       | Depression (1 point) | III | – | – | – |
| 13       | Depression (2 points) | III | – | – | ND |
| 14       | Depression (2 points) | II | – | – | – |
| 15       | Cerebral vasculitis (1 point) | II | – | – | – |
| 16       | Cerebral vasculitis (1 point) | II | – | – | ND |
| 17       | SCD (1 point) | III | – | + | – |
| 18       | SCD (1 point) | II | – | – | – |
| 19       | Stiff-person syndrome (1 point) | I | – | – | ND |

Abbreviations: AD = Alzheimer disease; ALS = amyotrophic lateral sclerosis; CBS = corticobasal syndrome; CIDP = chronic inflammatory demyelinating polyneuropathy; MSA-C = multiple system atrophy, cerebellar type; MSA-P = multiple system atrophy, parkinsonian type; ND = not done; PAF = pure autonomic failure; PD = Parkinson disease; PSP = progressive supranuclear palsy; SCD = subjective cognitive disorder.

* Patients from whom 10 skin samples were taken while in the remaining patients 8 skin samples were taken combining the routine and study protocols (see Methods for more details).
RT-QuIC Assay of CSF Samples

Next, the α-synuclein seeding activity of CSF was also detected by RT-QuIC assay. The cutoff point for defining the positive seeding activity was ThT fluorescence of 54.473 (au) based on the mean CSF α-synuclein ThT fluorescence intensity of control plus 3 SDs. The CSF RT-QuIC result yielded a sensitivity of 78% and specificity of 100% (table 2) in disclosing synucleinopathies without any non-synucleinopathies and control patients showing positive α-synuclein seeding activity (table 3). The mean CSF α-synuclein ThT fluorescence intensity from patients with synucleinopathies (n = 9) was significantly higher than that from patients with non-synucleinopathies (n = 24) (88.137 ± 14.177 [SE] vs 32.695 ± 3.819, au, p < 0.01) and controls (n = 16) (88.137 ± 14.177 vs 25.723 ± 2.442, au, p < 0.01). In contrast, there was no significant difference in CSF α-synuclein ThT fluorescence intensity between non-synucleinopathies and controls (32.695 ± 3.819 vs 25.723 ± 2.442, au, p = 0.45) (figure 3B). Regression models showed no influence of age, sex, or disease duration on the results.

Immunofluorescence vs RT-QuIC to Detect Pathologic α-Synuclein

The p-syn staining in skin nerves disclosed by immunofluorescence showed good agreement with the CSF RT-QuIC assay (κ = 0.9; p < 0.001) but the agreement was lower with skin RT-QuIC (κ = 0.6; p < 0.001) due to positive detection in skin samples by RT-QuIC in non-synucleinopathies (κ = 0.2; p = 0.08) and control patients (κ = 0.3; p < 0.05). For the same reason, skin RT-QuIC showed low agreement with CSF RT-QuIC considering all recruited patients (κ = 0.6; p < 0.001) but the agreement in synucleinopathies was optimal (κ = 1; p < 0.001).

χ² test showed that immunofluorescence better discriminates than RT-QuIC between positive vs negative patients among synucleinopathies, non-synucleinopathies, and control patients (χ² = 80.1 for immunofluorescence, χ² = 37.8 for skin RT-QuIC, and χ² = 36.3 for CSF RT-QuIC; p < 0.0001).

Discussion

The main findings of our study are that (1) both immunofluorescence and RT-QuIC showed a high diagnostic accuracy in differentiating synucleinopathies from different neurodegenerative and other neurologic disorders, although immunofluorescence displayed the better value as well as optimal reproducibility; and (2) these techniques presented a good level of agreement, supporting their equivalency for diagnostic purpose, although the agreement with skin RT-QuIC was lower in patients with non-synucleinopathies.

The correct diagnosis of synucleinopathies in living patients is a prominent challenge with several implications. The search for several biomarkers is in progress but a single diagnostic test with high sensitivity and specificity is not currently available for synucleinopathies, although urgently needed. Because autonomic symptoms may precede the classical symptoms of synucleinopathy, such as motor dysfunction in PD or dementia in DLB, reflecting the early damage of postganglionic sympathetic branches, peripheral tissues with extensive autonomic innervation, such as the skin, could be a useful target site in the search of pathologic forms of α-synuclein aggregates. The use of skin samples to identify biomarkers for synucleinopathies is also promising considering that skin biopsy is a minimally invasive procedure. The morphologic identification of misfolded α-synuclein aggregates as p-syn in skin nerves by means of immunofluorescence has been reported in all variants of synucleinopathies, allowing the distinction of these disorders from diseases of different origins or from healthy controls. Additional data showed that p-syn in skin nerves may also be used to differentiate MSA from PD or uncomplicated PD from PD associated with orthostatic hypotension.21 Furthermore, it

Figure 2 Real-Time Quaking-Induced Conversion (RT-QuIC) Spectra of Average Thioflavin T (ThT) Fluorescence Intensity of Skin α-Synuclein of Patients With Synucleinopathies or Non-Synucleinopathies
has recently been demonstrated by means of a meta-analysis that skin biopsy presented the best diagnostic accuracy in disclosing abnormal α-synuclein deposits in patients with PD.\(^{27}\) In addition, the reliability of immunofluorescence as a diagnostic tool has been supported by excellent interlaboratory and intralaboratory reproducibility.\(^{22}\)

RT-QuIC was formerly developed as a diagnostic tool for prion diseases using CSF\(^{9}\) or skin tissue.\(^{23,24}\) This test was recently adapted to detect the seeding activity of pathologic α-synuclein with brain, CSF, or skin samples\(^{10,28,29}\) from PD and LBD with high diagnostic accuracy. Although results are promising and support the clinical use of this technique, reproducibility studies with more cases are lacking.

Immunofluorescence and RT-QuIC explore different forms of pathologic α-synuclein. Immunofluorescence discloses the morphology of the pathologic form of α-synuclein in skin nerve fibers as it identifies the phosphorylation at ser129 of α-synuclein correlated to the change of conformation of the native state with specific antibodies.\(^{28}\) In contrast, RT-QuIC reveals the aggregation behavior of pathologic α-synuclein,\(^{23,24}\) a prion-like feature of misfolded proteins. For this reason, it is important to compare the diagnostic accuracy of the 2 approaches in disclosing a synucleinopathy. The clarification of this aspect may improve their adoption as a diagnostic tool for synucleinopathies in clinical practice.

Our study demonstrates that immunofluorescence staining of p-syn in skin nerves showed side-to-side optimal reproducibility in a large number of samples of both synucleinopathies and non-synucleinopathies. We found that immunofluorescence exhibited a good level of agreement with RT-QuIC (mainly CSF), supporting their equivalency as diagnostic tools for synucleinopathies. The exact reasons for the discrepancy between positive skin RT-QuIC and negative immunofluorescence, even in routine analysis, in some non-synucleinopathies and control patients remain to be clarified. Because the 2 approaches determine 2 different aspects of the α-synuclein aggregates as mentioned above, a possibility needs to be excluded in the future that there are unphosphorylated α-synuclein aggregates in the skin of patients with certain conditions and those aggregates may be detectable by only RT-QuIC for their prion-like seeding activity but not by immunofluorescence with antibodies for their phosphorylation. Accordingly, this finding could be the expression of a copathology (mixed pathology) in non-synucleinopathies.\(^{29}\) Similarly, α-synuclein aggregates in the skin sample of patients with neuropathies could be explained by an incidental synucleinopathy occasionally found on autopsy of decedents without showing clinical phenotypes. In addition, the intraneural p-syn deposits detected by immunofluorescence may not have been found in patients with peripheral neuropathy because of the decrease of the peripheral nerve fibers. However, this hypothesis is denied by the absence of p-syn in these patients even in skin sites with likely preserved skin innervation as cervical and thigh sites in routine analysis. We carefully re-evaluated patients with non-synucleinopathies and control patients found to be positive at the skin by RT-QuIC assay, but no clinical signs attributable to a synucleinopathy could be found, although to exclude this possibility patients should undergo a more extensive clinical follow-up.

The analysis of the diagnostic accuracy of single tests underlined that RT-QuIC presented high sensitivity and specificity in identifying synucleinopathies, as recently reported.\(^{28}\) However, in our study, we found that the greater diagnostic accuracy was given by immunofluorescence. In fact, this test provided higher sensitivity, with 90% of patients with synucleinopathies positive for p-syn, and the highest specificity, as p-syn staining was negative in all non-synucleinopathies and control patients. However, it should be underlined that the low number of patients undergoing CSF RT-QuIC may be responsible for the lower sensitivity of this test compared to immunofluorescence.

The current study presents the following limitations: (1) the lack of autopsy-confirmed diagnosis of recruited patients. This is a
significant limitation, although we recruited for this study only patients fulfilling accepted clinical criteria in agreement with the results of appropriated diagnostic tools. However, immunofluorescence or CSF RT-QuIC assay found a clear-cut difference among the 3 groups of investigated patients, supporting a correct selection of recruited patients; (2) the diagnostic accuracy in detecting a synucleinopathy in skin samples may be underestimated since the analysis has almost always been done in a single skin site addressed by the specific clinical phenotype, e.g., PD and DLB in proximal skin sites\(^\text{25}\) and MSA in distal sites,\(^\text{25,26,31,32}\) to simplify the study protocol and decrease the number of biopsies taken from each patient. However, abnormal aggregates of \(\alpha\)-synuclein may not be evenly distributed in skin nerves and a single site may not be sufficient to detect it precisely. A similar situation has been observed in RT-QuIC assay of prion-seeding activity in skin tissues from different body areas of cadavers with Creutzfeldt-Jakob disease diagnosed neuropathologically; in some cases, positive prion-seeding activity was not always detected in all 3 different skin samples and 1 or 2 skin areas could exhibit no detectable prion-seeding activity\(^\text{23}\); (3) the lack of quantitative MRI analysis to better differentiate tauopathies from synucleinopathies or TDP proteinopathies. However, a high diagnostic accuracy for synucleinopathies was reached by means of characteristic abnormalities on different diagnostic tools such as MRI, nigrostriatal SPECT, cardiac MIBG SPECT, or head-up tilt test.

This study deals with the important topic of the in vivo diagnosis of synucleinopathies by comparing immunofluorescence and RT-QuIC, 2 recently described advanced techniques to disclose pathologic aggregates of \(\alpha\)-synuclein. Our data demonstrate that both techniques displayed high diagnostic accuracy in differentiating synucleinopathies from other neurodegenerative and neurologic disorders, although immunofluorescence displayed the better value as well as an optimal reproducibility. In addition, these 2 diagnostic tools showed good agreement in disclosing a synucleinopathy, supporting the use in clinical practice of less invasive tests such as skin immunofluorescence or RT-QuIC instead of CSF as diagnostic tool for synucleinopathies.

**Acknowledgment**
The authors thank Johnny Dang for proofreading the manuscript.

**Study Funding**
Ricerca Finalizzata Ministero della Salute Grant RF-2016-02362047 to V.D. and A.I. and NIH (NS112010, NIH NS09532, NS096626) and ALZ/ARUK/MJFF/Weston to W.Z.

**Disclosure**
The authors report no conflicts of interest. Go to Neurology.org for full disclosures.

**Publication History**
Received by *Neurology* September 10, 2020. Accepted in final form February 24, 2021.

### References
1. Dorsey ER, Constantinidis R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. *Neurology* 2007; 68:384–386.
2. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. *Neurology* 2017; 89:88–100.
3. Koga S, Aoki N, Uitti RJ, et al. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. *Neurology* 2015;85:404–412.
4. Donadio V, Incensi A, Cortelli P, et al. Skin sympathetic fiber \(\alpha\)-synuclein deposits: a potential biomarker for pure autonomic failure. *Neurology* 2013;80:725–732.

**Appendix Authors**

| Name                  | Location                                                                 | Contribution                                                                                           |
|-----------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Vincenzo Donadio, MD, PhD | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy              | Conceived and designed the study, acquired, analyzed, managed and interpreted the data, wrote and revised the manuscript |
| Zerui Wang, MD, PhD     | Departments of Pathology and Neurology, Case Western Reserve University School of Medicine, Cleveland, OH | Acquired, analyzed, managed, and interpreted the data                                                   |
| Alex Incensi, BSc       | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy              | Acquired, analyzed, managed, and interpreted the data                                                   |
| Giovanni Rizzo, MD       | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy              | Acquired, analyzed, managed, and interpreted the data                                                   |
| Enrico Fileccia, MD      | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy              | Acquired the data                                                                                      |
| Veria Vacchiano, MD      | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy              | Acquired the data                                                                                      |
| Sabina Capellari, MD, PhD | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy              | Acquired the data                                                                                      |
| Martina Magnani, BSc     | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy              | Acquired the data                                                                                      |
| Cesa Scaglione, MD       | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy              | Acquired the data                                                                                      |
| Michelangelo Stanzani Maserati, MD | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy             | Acquired the data                                                                                      |
| Patrizia Avoni, MD, PhD   | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy              | Acquired the data                                                                                      |
| Rocco Liguori, MD        | IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy              | Conceived and designed the study, acquired, analyzed, managed, interpreted the data, and revised the manuscript |
| Wenquan Zou, MD, PhD     | Departments of Pathology and Neurology, Case Western Reserve University School of Medicine, Cleveland, OH | Conceived and designed the study, acquired, analyzed, managed, and interpreted the data, wrote and revised the manuscript |
5. Doppler K, Ebert S, Üçeyler N, et al. Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology. Acta Neuropathol 2014;128:99–109.
6. Donadio V, Incensi A, Rizzo G, et al. A new potential biomarker for dementia with Lewy bodies: skin nerve α-synuclein deposits. Neurology 2017;89:318–326.
7. Doppler K, Wea J, Karl K, et al. Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophy. Mov Disord 2015;30:1688–1692.
8. Donadio V. Skin nerve α-synuclein deposits in Parkinson’s disease and other synucleinopathies: a review. Clin Auton Res 2019;29:577–585.
9. Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 2011;17:175–178.
10. Groveman BR, Orrú CD, Hughson AG, et al. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathol Commun 2018;6:7.
11. Duits FH, Teunissen CE, Bouwman FH, et al. The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean? Alzheimer’s Dement 2014;10:713–723.
12. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9.
13. Bak TH, Hodges JR. Corticobasal degeneration. In: Vinken PJ, Bruyn GW, eds. Handbook of Clinical Neurology, vol 89. Elsevier Science; 2008:509–511.
14. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the MDS-SPSP international workshop. Neurology 1996;47:1–9.
15. Duits FH, Teunissen CE, Bouwman FH, et al. The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean? Alzheimer’s Dement 2014;10:713–723.
16. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the MDS-SPSP international workshop. Neurology 1996;47:1–9.
17. Román GC, Sachdev P, Royall DR, et al. Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 2004;226:81–87.
18. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416–418.
19. De CarvalhoDengler MR, Eisen A, England JD, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008;119:497–503.
20. Gallassi R, Lenzi P, Stracciari A, et al. Neuropsychological assessment of mental deterioration: purpose of a brief battery and a probabilistic definition of “normality” and “non-normality”. Acta Psychiatr Scan 1986;75:62–67.
21. Donadio V, Incensi A, Del Sorbo F, et al. Skin nerve phosphorylated α-synuclein deposits in Parkinson’s disease with orthostatic hypotension. J Neuropathol Exp Neurol 2018;77:942–949.
22. Donadio V, Doppler K, Incensi A, et al. Abnormal α-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility. Eur J Neurol 2019;26:1245–1251.
23. Orrú CD, Yuan J, Appleby BS, et al. Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. Sci Transl Med 2017;9:eaaam7785.
24. Wang Z, Manca M, Foutz A, et al. Early preclinical detection of prions in the skin of prion-infected animals. Nat Commun 2019;10:247.
25. Donadio V, Incensi A, El-Agnaf O, et al. Skin α-synuclein deposits differ in clinical variants of synucleinopathies: an in vivo study. Sci Rep 2018;8:14246.
26. Donadio V, Incensi A, Rizzo G, et al. Skin biopsy may help to distinguishing MSA-P from Parkinson’s disease with orthostatic hypotension. Mov Disord 2020;35:1649–1657.
27. Tsukita K, Sakamaki-Tsukita H, Tanaka K, Suenaga T, Takahashi R. Value of in vivo α-synuclein deposits in Parkinson’s disease with orthostatic hypotension. Mov Disord 2010;25:1657–1663.
28. Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 2020;140:1–9.
29. Wang Z, Becker K, Donadio V, et al. Skin α-synuclein aggregation seeding activity as a novel biomarker for Parkinson Disease. JAMA Neurol 2020;78:1–11.
30. Rossi M, Candelise N, Baiardi S, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. Acta Neuropathol 2020;140:1–9.
31. Isonaka R, Rosenberg AZ, Sullivan P, et al. Alpha-synuclein deposition within symmetrical associations of amyloid plaques in Lewy body disease. Acta Neuropathol 2013;125:1–11.
32. Isonaka R, Gibbons CH, Wang N, Freeman R, Goldstein DS. Association of multiple system atrophy. Neurology 2008;71:670–676.
In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC
Vincenzo Donadio, Zerui Wang, Alex Incensi, et al.
Neurology 2021;96:e2513-e2524 Published Online before print April 9, 2021
DOI 10.1212/WNL.0000000000011935

This information is current as of April 9, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/96/20/e2513.full

References
This article cites 32 articles, 10 of which you can access for free at:
http://n.neurology.org/content/96/20/e2513.full#ref-list-1

Citations
This article has been cited by 5 HighWire-hosted articles:
http://n.neurology.org/content/96/20/e2513.full##otherarticles

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Class III
http://n.neurology.org/cgi/collection/class_iii
Dementia with Lewy bodies
http://n.neurology.org/cgi/collection/dementia_with_lewy_bodies
Parkinson disease/Parkinsonism
http://n.neurology.org/cgi/collection/parkinsons_disease_parkinsonism

Errata
An erratum has been published regarding this article. Please see next page or:
/content/99/1/40.full.pdf

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise
Editors’ Note: Shoulder-Tap Test for Functional Gait Disorders: A Sign of Abnormal Anticipatory Behavior

Dr. Coebergh and colleagues described exaggerated postural responses in 25 patients with functional gait disorders, following a sudden shoulder tap applied by an examiner from behind the patient. In response, Dr. Geroin et al. comment that in their own population of patients with functional neurologic disorders, a light touch on the shoulders seemed to provide fewer false-positive results, given that a sudden tap could evoke exaggerated responses in patients with disorders such as hyperekplexia or stiff-person syndrome. They also note that it is not necessary to see an intact response to a retropulsion test in patients with functional gait disorders to flag their shoulder-test response as incongruent. Responding to these comments, Dr. Coebergh agrees that a light touch would likely suffice, noting that the actual contact with the shoulders in the described shoulder-tap test is light, while also highlighting work being performed by their group in identifying sensory thresholds of force at which incongruent postural responses occur in such patients. To illustrate the potential value of observing incongruity in responses to shoulder-tap vs retropulsive stimuli in patients with functional gait disorder, Dr. Coebergh highlights a case of a patient with stiff-person syndrome misdiagnosed as a functional neurologic disorder, in whom such incongruity was not observed. This exchange demonstrates the enduring value of systematic clinical examinations and observations in improving the diagnosis of functional neurologic disorders.

Christian Geroin (Verona, Italy), Jorik Nonnekes (Nijmegen, the Netherlands), Serena Camozzi (Verona, Italy), Bastiaan R. Bloem (Nijmegen, the Netherlands), and Michele Tinazzi (Verona, Italy)
Neurology® 2022;99:38-39. doi:10.1212/WNL.0000000000200865

Reader Response: Shoulder-Tap Test for Functional Gait Disorders: A Sign of Abnormal Anticipatory Behavior

In a recent report, Coebergh et al. introduced the shoulder-tap test, which helps to reveal incongruity in patients with functional gait disorders. Specifically, the authors observed an exaggerated postural response in 82% of patients, following a gentle shoulder tap applied from behind the patient. We applaud the described approach because incongruencies of symptoms and signs have great diagnostic value when diagnosing a functional neurologic disorder. We hope to extend the findings of Coebergh et al. by making 2 additional points.

As observed in our population of functional neurologic disorders, a light touch on the shoulders instead of a shoulder tap might be more informative and provide fewer false-positive results because a sudden tap can evoke an exaggerated postural response in patients with hyperekplexia or stiff-person syndrome. This movement would then incorrectly be classified as an incongruent response. In addition, the authors state that incongruity involves an abnormal response to the shoulder tap combined with an intact response to the normal retropulsion test. We would argue...
that an isolated abnormal response to a mere touch to the shoulders would already suggest incongruity, with a consideration for rare organic disorders such as hyperekplexia and stiff-person syndrome.

1. Coebergh J, Zimianiti I, Kaski D. Shoulder-tap test for functional gait disorders: a sign of abnormal anticipatory behavior. Neurology. 2021;97(23):1070-1071.
2. Espay AJ, Aybek S, Canon A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol. 2018;75(9):1132-1141.
3. Nonnekes J, Růžička E, Serranová T, Reich SG, Bloem BR, Hallett M. Functional gait disorders: a sign-based approach. Neurology. 2020;94(24):1093-1099.
4. Gupta A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol. 2009;22(4):430-436.

We welcome the comments by Dr. Geroin et al. on our article. We agree that a light touch may be a sufficient stimulus to induce an anticipatory postural response in patients with functional gait disorders, without the need for a “tap.” Although the video linked to our article shows a rapid downward movement of the examiner’s hands onto the shoulders, the actual contact with the shoulders is in fact light, lending credence to our esteemed colleagues’ observations. Whether there exists a sensory threshold of force, at which an incongruent or inappropriate postural response occurs following a touch to the shoulders, is an interesting question that we hope to be able to address in our future work. In fact, we are extending our work to explore the shoulder-tap test in elderly people with a fear of falling—a common symptom in which abnormal anticipatory behaviors likely exist and identification of such thresholds may be of particular interest.

We also agree that an abnormal response to a light shoulder tap would be an incongruent response to such a stimulus, but, as we describe in our article, a normal response to a retro-pulsive stimulus or a pull after an abnormal shoulder tap provides further evidence of incongruity.

Finally, we have recently seen a patient with stiff-person syndrome who had been previously misdiagnosed as having a functional neurologic disorder; the clue to the actual diagnosis, beyond the presence of auditory startle and hyperlordosis, was indeed the absence of any incongruity in postural responses. We therefore appreciate the comments regarding this rare but treatable disorder and the importance of avoiding undue force during a shoulder tap or touch that would render interpretation of the ensuing behavior more challenging.

1. Coebergh J, Zimianiti I, Kaski D. Shoulder-tap test for functional gait disorders: a sign of abnormal anticipatory behavior. Neurology. 2021;97(23):1070-1071.

Copyright © 2022 American Academy of Neurology

Author Response: Shoulder-Tap Test for Functional Gait Disorders: A Sign of Abnormal Anticipatory Behavior

Jan A. Coebergh (Chertsey, UK)
Neurology® 2022;99:39. doi:10.1212/WNL.000000000000200867

We welcome the comments by Dr. Geroin et al. on our article. We agree that a light touch may be a sufficient stimulus to induce an anticipatory postural response in patients with functional gait disorders, without the need for a “tap.” Although the video linked to our article shows a rapid downward movement of the examiner’s hands onto the shoulders, the actual contact with the shoulders is in fact light, lending credence to our esteemed colleagues’ observations. Whether there exists a sensory threshold of force, at which an incongruent or inappropriate postural response occurs following a touch to the shoulders, is an interesting question that we hope to be able to address in our future work. In fact, we are extending our work to explore the shoulder-tap test in elderly people with a fear of falling—a common symptom in which abnormal anticipatory behaviors likely exist and identification of such thresholds may be of particular interest.

We also agree that an abnormal response to a light shoulder tap would be an incongruent response to such a stimulus, but, as we describe in our article, a normal response to a retro-pulsive stimulus or a pull after an abnormal shoulder tap provides further evidence of incongruity.

Finally, we have recently seen a patient with stiff-person syndrome who had been previously misdiagnosed as having a functional neurologic disorder; the clue to the actual diagnosis, beyond the presence of auditory startle and hyperlordosis, was indeed the absence of any incongruity in postural responses. We therefore appreciate the comments regarding this rare but treatable disorder and the importance of avoiding undue force during a shoulder tap or touch that would render interpretation of the ensuing behavior more challenging.

1. Coebergh J, Zimianiti I, Kaski D. Shoulder-tap test for functional gait disorders: a sign of abnormal anticipatory behavior. Neurology. 2021;97(23):1070-1071.

Copyright © 2022 American Academy of Neurology

Author disclosures are available upon request (journal@neurology.org).
In the article “In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC” by Donadio et al., the first paragraph of the Methods section should indicate that of the 31

Table 4 Immunofluorescence and Real-Time Quaking-Induced Conversion (RT-QuIC) Results of Skin and CSF Samples

| Variable                  | Cases, n | Diagnosis                     | Skin Protocol | Immunofluorescence | RT-QuIC | CSF, RT-QuIC |
|---------------------------|----------|-------------------------------|---------------|-------------------|---------|--------------|
| Synucleinopathies         | 1        | PD (1 patient)*               | III           | +                 | +       | +            |
|                           | 2        | PD (6 patients*)              | III           | +                 | +       | ND           |
|                           | 3        | PD (1 patient)                | II            | +                 | +       | +            |
|                           | 4        | PD (3 patients*)              | II            | +                 | +       | ND           |
|                           | 5        | PD (5 patients)               | III           | +                 | +       | ND           |
|                           | 6        | PD (1 patient*)               | I             | –                 | +       | ND           |
|                           | 7        | MSA-C (1 patient)             | III           | +                 | +       | +            |
|                           | 8        | MSA-P (3 patients)            | I             | +                 | +       | ND           |
|                           | 9        | MSA-P (1 patient)             | I             | –                 | –       | ND           |
|                           | 10       | MSA-P (1 patient)             | I             | +                 | –       | ND           |
|                           | 11       | MSA-P (1 patient)             | I             | –                 | +       | ND           |
|                           | 12       | MSA-C (1 patient)             | I             | +                 | –       | ND           |
|                           | 13       | Lewy body dementia (1 patient)| III           | +                 | –       | ND           |
|                           | 14       | Lewy body dementia (2 patients)| II          | +                 | +       | +            |
|                           | 15       | Lewy body dementia (1 patient)| I             | +                 | +       | +            |
|                           | 16       | Lewy body dementia (1 patient)| I             | +                 | +       | ND           |
|                           | 17       | PAF (1 patient)               | II            | +                 | +       | +            |
|                           | 18       | PAF (1 patient)               | II            | –                 | –       | –            |
|                           | 19       | PAF (1 patient)               | I             | +                 | –       | –            |
| Nonsynucleinopathies      | 1        | AD (5 patients)               | III           | –                 | –       | –            |
|                           | 2        | AD (2 patients)               | III           | –                 | +       | –            |
|                           | 3        | AD (1 patient)                | III           | –                 | –       | ND           |
|                           | 4        | AD (1 patient)                | III           | –                 | +       | ND           |
|                           | 5        | AD (2 patients)               | II            | –                 | –       | –            |
|                           | 6        | AD (1 patient)                | II            | –                 | –       | –            |
|                           | 7        | AD (2 patients)               | I             | –                 | –       | –            |
|                           | 8        | AD (1 patient)                | I             | –                 | –       | ND           |
|                           | 9        | PSP (1 patient)               | III           | –                 | +       | ND           |
|                           | 10       | PSP (2 patients)              | II            | –                 | –       | –            |

Continued
Table 4  Immunofluorescence and Real-Time Quaking-Induced Conversion (RT-QuIC) Results of Skin and CSF Samples
(continued)

| Variable                  | Cases, n | Diagnosis                           | Skin Protocol | Immunofluorescence | RT-QuIC | CSF, RT-QuIC |
|---------------------------|----------|-------------------------------------|---------------|--------------------|---------|--------------|
| 11                        | CBS (1 patient) | II                                  | −             | −                  | ND      |
| 12                        | CBS (1 patient) | II                                  | −             | +                  | ND      |
| 13                        | Vascular parkinsonism (3 patients*) | III                     | −             | −                  | ND      |
| 13                        | Vascular parkinsonism (1 patient)  | II                     | −             | −                  | ND      |
| 14                        | Vascular parkinsonism (2 patients*) | II                     | −             | −                  | ND      |
| 15                        | Vascular parkinsonism (2 patients) | I                      | −             | −                  | −       |
| 16                        | Iatrogenic parkinsonism (1 patient) | I                     | −             | −                  | ND      |
| 17                        | Autoimmune parkinsonism (1 patient) | II                     | −             | −                  | ND      |
| 18                        | Vascular dementia (1 patient)       | III                    | −             | −                  | −       |
| 19                        | Vascular dementia (1 patient)       | II                     | −             | +                  | −       |
| 20                        | ALS (1 patient)                     | III                    | −             | +                  | −       |
| 21                        | ALS (1 patient)                     | II                     | −             | +                  | −       |
| 22                        | ALS (3 patients)                    | I                      | −             | −                  | −       |
| 23                        | ALS (1 patient)                     | I                      | −             | +                  | ND      |
| Controls                  |          |                                     |               |                    |         |
| 1                         | Small fiber neuropathy (3 patients) | III                    | −             | −                  | −       |
| 2                         | Small fiber neuropathy (2 patients) | III                    | −             | −                  | ND      |
| 3                         | Small fiber neuropathy (1 patient)  | I                      | −             | −                  | −       |
| 4                         | Small fiber neuropathy (1 patient)  | I                      | −             | −                  | −       |
| 5                         | Peripheral neuropathy (1 patient)   | III                    | −             | +                  | ND      |
| 6                         | Peripheral neuropathy (1 patient)   | II                     | −             | −                  | ND      |
| 7                         | Peripheral neuropathy (1 patient)   | II                     | −             | +                  | −       |
| 8                         | Peripheral neuropathy (1 patient)   | I                      | −             | −                  | −       |
| 9                         | Peripheral neuropathy (1 patient)   | I                      | −             | −                  | −       |
| 10                        | CIDP (1 patient)                     | I                      | −             | −                  | −       |
| 11                        | Wernicke encephalopathy (1 patient) | I                      | −             | −                  | −       |
| 12                        | Depression (1 patient)              | III                    | −             | −                  | −       |
| 13                        | Depression (2 patients)             | III                    | −             | −                  | ND      |
| 14                        | Depression (2 patients)             | II                     | −             | −                  | −       |
| 15                        | Cerebral vasculitis (1 patient)     | II                     | −             | −                  | −       |
| 16                        | Cerebral vasculitis (1 patient)     | II                     | −             | ND                 | −       |
| 17                        | SCD (1 patient)                     | III                    | −             | +                  | −       |
| 18                        | SCD (1 patient)                     | II                      | −             | −                  | −       |
| 19                        | Stiff-person syndrome (1 patient)   | I                      | −             | −                  | ND      |

Abbreviations: AD = Alzheimer disease; ALS = amyotrophic lateral sclerosis; CBS = corticobasal syndrome; CIDP = chronic inflammatory demyelinating polyneuropathy; MSA-C = multiple system atrophy, cerebellar type; MSA-P = multiple system atrophy, parkinsonian type; ND = not done; PAF = pure autonomic failure; PD = Parkinson disease; PSP = progressive supranuclear palsy; SCD = subjective cognitive disorder.

* Patients from whom 10 skin samples were taken; in the remaining patients, 8 skin samples were taken combining the routine and study protocols (see Methods for more details).
patients with synucleinopathies, 15 were patients with Parkinson disease, and of the 38 patients with nonsynucleinopathies, 7 were patients with vascular parkinsonism. The authors regret the errors.

In addition, the Diagnosis column of Table 4 should read “patients” in parentheses, not “points.” See the corrected Table 4. The publisher regrets the errors.

Reference
1 Donadio V, Wang Z, Incensi A, et al. In vivo diagnosis of synucleinopathies: a comparative study of skin biopsy and RT-QuIC. Neurology. 2021;96(20): e2513-e2524.

NOTICE
Dual Publication: Spinal Cord Injury, Vertebral Artery Dissection, and Cerebellar Strokes After Chiropractic Manipulation

Neurology® 2022;99:42. doi:10.1212/WNL.00000000000200334

The Editors of Neurology® and Internal and Emergency Medicine issue a notice of publication of 2 reports of a single patient written by 2 different author groups.

Macêdo MB, Shinjo SK, Domiciano DS. Breaking the Diagnosis: Ankylosing Spondylitis Evidenced by Cervical Fracture following Spine Manipulation. Intern Emerg Med 2021. DOI: 10.1007/s11739-021-02829-2.

Ramos GB, Martins RR, Souza JCC, Falcão FCSEB, Lopes CCB, Andrade ALG, Silva GD. Spinal Cord Injury, Vertebral Artery Dissection, and Cerebellar Strokes after Chiropractic Manipulation. Neurology 2021. DOI: 10.1212/WNL.0000000000013078.

The first article was published in Internal and Emergency Medicine. The journal received it on July 20, 2021, accepted it on August 10, 2021, and published it online on August 20, 2021. The second article was published in Neurology. It was received on July 16, 2021, accepted on November 4, 2021, and published online on November 18, 2021. The 2 case reports were based on the same patient and shared a common image.

Both case reports were written by authors from the Faculdade de Medicina, Universidade de São Paulo. The authors of the article published in Internal and Emergency Medicine were affiliated with the Department of Rheumatology, and the authors of the Neurology article were affiliated with the Department of Neurology.

The authors of both articles were contacted and asked for an explanation for the dual publication. Both teams of authors explained that they cared for the patient during the hospital admission and that they were unaware of the submission by the other team. The focus of the articles is different: one focused on bone injury and emergency care and the other on the neurologic aspects of the case. Both author groups apologize for the duplicate submissions.

A reader first notified Neurology that the case had been published in the 2 journals and a brief report was submitted to Neurology’s Disputes & Debates section on November 29, 2021.¹

Reference
1. Trager RJ, Garcia JA. Disputes & Debates: Rapid Online Correspondence. Reader Response: Spinal Cord Injury, Vertebral Artery Dissection, and Cerebellar Strokes after Chiropractic Manipulation. n.neurology.org/content/reader-response-spinal-cord-injury-vertebral-artery-dissection-and-cerebellar-strokes after.

Copyright © 2022 American Academy of Neurology